OKLAHOMA CITY, Nov. 12 For the fiscal year ending June 30th, 2009, PD-Rx (Pink Sheets: PDRX) set record sales of $26.9 million over last year's sales figures of $26.4 million, reporting a net increase in sales of $493,230. Net profits increased by 22.6% in 2009 to $912,952 up from $706,434 in 2008. Total assets in 2009 increased by 11.7% to $6,379,890 up from $5,628,778 in 2008. While total liabilities in 2009 decreased to $1,349,647 from $1,511,487 in 2008.
Advertisement
Stockholders equity increased to $5,030,243 in 2009 up from $4,117,291 in 2008. Earnings per share for fiscal year 2009 was $0.53 per common share (basic) and $0.52 per common share fully diluted compared to $0.42 and $.40 per share respectively in 2008.
Advertisement
ABOUT THE COMPANY:
PD-Rx offers pharmaceutical and management strategies to the healthcare industry. Our management strategies focus on new products, solid business partners, and the specialized segment of the pharmaceutical industry. As a licensed FDA manufacturer and packager, PD-Rx offers a full spectrum of medications and specialized services. Our goal is to develop a matrix of cost containment tools and products that we can merge into any healthcare network to enhance patient care and improve managed care organizations bottom line. We provide proprietary products and prepackaged medications that are viewed by patient, insurance payers and healthcare providers as a progressive and responsive practice.
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks and uncertainties or other factors, which may cause actual results, performance or achievements expressed or implied by such forward-looking statements to vary from those forecast or implied in this release. Factors that might cause such a difference include, without limitation, decline in demand for the company's products or services, and the effect of general economic conditions and factors affecting the industry.
For Further Information, Contact: Jack L. McCall, EVP & COO Ph. 405-942-3040 / [email protected]
SOURCE PD-Rx Pharmaceuticals, Inc.
